Levoxyl (levothyroxine sodium) Tablet
[King Pharmaceuticals, Inc.]
DESCRIPTION
–LEVOXYL® (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3’,5,5’-
tetraiodothyronine sodium salt [levothyroxine (T ) sodium]. Synthetic T is identical to that 4 4 produced in the human thyroid gland. Levothyroxine (T ) sodium has an empirical formula of 4 C H I N NaO • H O, molecular weight of 798.86 g/mol (anhydrous), and structural formula 15 10 4 4 2 as shown:
Inactive Ingredients
Microcrystalline cellulose, croscarmellose sodium and magnesium stearate. The following are
the coloring additives per tablet strength:
Strength (mcg) Color additive(s)
25 FD&C Yellow No. 6 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake, D&C Red No. 30 Aluminum Lake
FD&C Yellow No. 6 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake,
D&C Yellow No. 10 Aluminum Lake
FD&C Red No. 40 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake, D&C Red No. 30 Aluminum Lake
FD&C Blue No. 1 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake
200 D&C Red No. 30 Aluminum Lake, D&C Yellow No. 10 Aluminum Lake
75
88
1
100 FD&C Yellow No. 6 Aluminum Lake, D&C Yellow No. 10 Aluminum
Lake
112 FD&C Yellow No. 6 Aluminum Lake, FD&C Red No. 40 Aluminum Lake,
D&C Red No. 30 Aluminum Lake
25
137
150
175
50 None
CLINICAL PHARMACOLOGY
Thyroid hormone synthesis and secretion is regulated by the hypothalamic-pituitary-thyroid
axis. Thyrotropin-releasing hormone (TRH) released from the hypothalamus stimulates
secretion of thyroid-stimulating hormone, TSH, from the anterior pituitary. TSH, in turn, is the
physiologic stimulus for the synthesis and secretion of thyroid hormones, L-thyroxine (T ) and 4 L-triiodothyronine (T ), by the thyroid gland. Circulating serum T3 3 and T4 levels exert a feedback effect on both TRH and TSH secretion. When serum T 3 and T4 levels increase, TRH and TSH secretion decrease. When thyroid hormone levels decrease, TRH and TSH secretion
increase.
The mechanisms by which thyroid hormones exert their physiologic actions are not completely
understood, but it is thought that their principal effects are exerted through control of DNA
transcription and protein synthesis. T 3 and T4 diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene
transcription and synthesis of messenger RNA and cytoplasmic proteins.
Thyroid hormones regulate multiple metabolic processes and play an essential role in normal
growth and development, and normal maturation of the central nervous system and bone. The
metabolic actions of thyroid hormones include augmentation of cellular respiration and
thermogenesis, as well as metabolism of proteins, carbohydrates and lipids. The protein
anabolic effects of thyroid hormones are essential to normal growth and development.
The physiologic actions of thyroid hormones are produced predominately by T , the majority of 3 which (approximately 80%) is derived from T 4 by deiodination in peripheral tissues.
Levothyroxine, at doses individualized according to patient response, is effective as
replacement or supplemental therapy in hypothyroidism of any etiology, except transient
hypothyroidism during the recovery phase of subacute thyroiditis.
Levothyroxine is also effective in the suppression of pituitary TSH secretion in the treatment or
prevention of various types of euthyroid goiters, including thyroid nodules, Hashimoto’s
thyroiditis, multinodular goiter and, as adjunctive therapy in the management of thyrotropin-
dependent well-differentiated thyroid cancer (see INDICATIONS AND USAGE ,
PRECAUTIONS , DOSAGE AND ADMINISTRATION ).
Pharmacokinetics
Absorption — Absorption of orally administered T 4 from the gastrointestinal (GI) tract ranges from 40% to 80%. The majority of the levothyroxine dose is absorbed from the jejunum and
upper ileum. The relative bioavailability of LEVOXYL® tablets, compared to an equal nominal
dose of oral levothyroxine sodium solution, is approximately 98%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybean
infant formula. Dietary fiber decreases bioavailability of T . Absorption may also decrease with 4 age. In addition, many drugs and foods affect T 4 absorption (see PRECAUTIONS , DrugInteractions and Drug-Food Interactions ).
Distribution — Circulating thyroid hormones are greater than 99% bound to plasma proteins,
including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin
(TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG
and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T compared to T . Protein-bound thyroid hormones exist in reverse 4 3 equilibrium with small amounts of free hormone. Only unbound hormone is metabolically
active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum
proteins (see PRECAUTIONS , Drug Interactions and Drug-Laboratory Test Interactions).
Thyroid hormones do not readily cross the placental barrier (see PRECAUTIONS ,
Pregnancy).
Metabolism — T4 is slowly eliminated (see TABLE 1). The major pathway of thyroid hormone
metabolism is through sequential deiodination. Approximately eighty-percent of circulating T3 is derived from peripheral T by monodeiodination. The liver is the major site of degradation for 4 both T and T , with T deiodination also occurring at a number of additional sites, including4 3 4 the kidney and other tissues. Approximately 80% of the daily dose of T 4 is deiodinated to yield equal amounts of T and reverse T (rT ). T and rT are further deiodinated to 3 3 3 3 3 diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and
sulfates and excreted directly into the bile and gut where they undergo enterohepatic
recirculation.
Elimination — Thyroid hormones are primarily eliminated by the kidneys. A portion of the
conjugated hormone reaches the colon unchanged and is eliminated in the feces.
Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.
Table 1: Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
Hormone Ratio in
Thyroglobulin
Biologic
Potency
1/2 Protein Binding
(%)
Levothyroxine (T )
Liothyronine (T )
10—20
1
1
4
6—7
≤ 2
99.96
99.5
3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism; Includes TBG, TBPA,
and TBA
t (days)
2
4
3
1
1 2
INDICATIONS AND USAGE
Levothyroxine sodium is used for the following indications:
Hypothyroidism — As replacement or supplemental therapy in congenital or acquired
hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of
subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and
tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism
may result from functional deficiency, primary atrophy, partial or total congenital absence of the
thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of
goiter.
Pituitary TSH Suppression — In the treatment or prevention of various types of euthyroid
goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS
and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis),
multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and
radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid
cancer.
CONTRAINDICATIONS
Levothyroxine is contraindicated in patients with untreated subclinical (suppressed serum TSH
level with normal T 3 and T 4 levels) or overt thyrotoxicosis of any etiology and in patients with acute myocardial infarction. Levothyroxine is contraindicated in patients with uncorrected
adrenal insufficiency since thyroid hormones may precipitate an acute adrenal crisis by
increasing the metabolic clearance of glucocorticoids (see PRECAUTIONS ). LEVOXYL ® is
contraindicated in patients with hypersensitivity to any of the inactive ingredients in LEVOXYL®
tablets (see DESCRIPTION , Inactive Ingredients ).
WARNINGS
WARNING: Thyroid hormones, including LEVOXYL , either alone or with other
therapeutic agents, should not be used for the treatment of obesity or for weight loss.
In euthyroid patients, doses within the range of daily hormonal requirements are
ineffective for weight reduction. Larger doses may produce serious or even life
threatening manifestations of toxicity, particularly when given in association with
sympathomimetic amines such as those used for their anorectic effects.
®
Levothyroxine sodium should not be used in the treatment of male or female infertility unless
this condition is associated with hypothyroidism.
In patients with nontoxic diffuse goiter or nodular thyroid disease, particularly the elderly or
those with underlying cardiovascular disease, levothyroxine sodium therapy is contraindicated
if the serum TSH level is already suppressed due to the risk of precipitating overt
thyrotoxicosis (see CONTRAINDICATIONS ). If the serum TSH level is not suppressed,
LEVOXYL® should be used with caution in conjunction with careful monitoring of thyroid
function for evidence of hyperthyroidism and clinical monitoring for potential associated
adverse cardiovascular signs and symptoms of hyperthyroidism.
PRECAUTIONS
General
Levothyroxine has a narrow therapeutic index. Regardless of the indication for use, careful
dosage titration is necessary to avoid the consequences of over- or under-treatment. These
consequences include, among others, effects on growth and development, cardiovascular
function, bone metabolism, reproductive function, cognitive function, emotional state,
gastrointestinal function, and on glucose and lipid metabolism. Many drugs interact with
levothyroxine sodium necessitating adjustments in dosing to maintain therapeutic response
(see Drug Interactions ).
Effects on bone mineral density — In women, long-term levothyroxine sodium therapy has
been associated with decreased bone mineral density, especially in postmenopausal women
on greater than replacement doses or in women who are receiving suppressive doses of
levothyroxine sodium. Therefore, it is recommended that patients receiving levothyroxine
sodium be given the minimum dose necessary to achieve the desired clinical and biochemical
response.
Patients with underlying cardiovascular disease — Exercise caution when administering
levothyroxine to patients with cardiovascular disorders and to the elderly in whom there is an
increased risk of occult cardiac disease. In these patients, levothyroxine therapy should be
initiated at lower doses than those recommended in younger individuals or in patients without
cardiac disease (see WARNINGS ; PRECAUTIONS , Geriatric Use ; and DOSAGE AND
ADMINISTRATION ). If cardiac symptoms develop or worsen, the levothyroxine dose should
be reduced or withheld for one week and then cautiously restarted at a lower dose.
Overtreatment with levothyroxine sodium may have adverse cardiovascular effects such as an
increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate
angina or arrhythmias. Patients with coronary artery disease who are receiving levothyroxine
therapy should be monitored closely during surgical procedures, since the possibility of
precipitating cardiac arrhythmias may be greater in those treated with levothyroxine.
Concomitant administration of levothyroxine and sympathomimetic agents to patients with
coronary artery disease may precipitate coronary insufficiency.
Patients with nontoxic diffuse goiter or nodular thyroid disease — Exercise caution when
administering levothyroxine to patients with nontoxic diffuse goiter or nodular thyroid disease in
order to prevent precipitation of thyrotoxicosis (see WARNINGS ). If the serum TSH is already
suppressed, levothyroxine sodium should not be administered (see CONTRAINDICATIONS )
Associated endocrine disorders
Hypothalamic/pituitary hormone deficiencies — In patients with secondary or tertiary
hypothyroidism, additional hypothalamic/pituitary hormone deficiencies should be considered,
and, if diagnosed, treated (see PRECAUTIONS , Autoimmune polyglandular syndrome) for
adrenal insufficiency.
Autoimmune polyglandular syndrome — Occasionally, chronic autoimmune thyroiditis may
occur in association with other autoimmune disorders such as adrenal insufficiency, pernicious
anemia, and insulin-dependent diabetes mellitus. Patients with concomitant adrenal
insufficiency should be treated with replacement glucocorticoids prior to initiation of treatment
with levothyroxine sodium. Failure to do so may precipitate an acute adrenal crisis when
thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids
by thyroid hormone. Patients with diabetes mellitus may require upward adjustments of their
antidiabetic therapeutic regimens when treated with levothyroxine (see PRECAUTIONS , Drug
Interactions ).
Other associated medical conditions
Infants with congenital hypothyroidism appear to be at increased risk for other congenital
anomalies, with cardiovascular anomalies (pulmonary stenosis, atrial septal defect, and
ventricular septal defect,) being the most common association.
Information for Patients
Patients should be informed of the following information to aid in the safe and effective use of ®LEVOXYL :
1. Notify your physician if you are allergic to any foods or medicines, are pregnant or intend
to become pregnant, are breast-feeding or are taking any other medications, including
prescription and over-the-counter preparations.
2. Notify your physician of any other medical conditions you may have, particularly heart
disease, diabetes, clotting disorders, and adrenal or pituitary gland problems. Your dose
of medications used to control these other conditions may need to be adjusted while you
are taking LEVOXYL®. If you have diabetes, monitor your blood and/or urinary glucose
levels as directed by your physician and immediately report any changes to your
physician. If you are taking anticoagulants (blood thinners), your clotting status should be
checked frequently.
3. Use LEVOXYL® only as prescribed by your physician. Do not discontinue or change the
amount you take or how often you take it, unless directed to do so by your physician.
4. The levothyroxine in LEVOXYL® is intended to replace a hormone that is normally
produced by your thyroid gland. Generally, replacement therapy is to be taken for life,
except in cases of transient hypothyroidism, which is usually associated with an
inflammation of the thyroid gland (thyroiditis).
5. Take LEVOXYL® in the morning on an empty stomach, at least one-half hour before
eating any food.
6. LEVOXYL® may rapidly swell and disintegrate resulting in choking, gagging, the tablet
getting stuck in your throat or difficulty swallowing. It is very important that you take the
tablet with a full glass of water. Most of these problems disappeared when Levoxyl ®
tablets were taken with water.
7. It may take several weeks before you notice an improvement in your symptoms.
8. Notify your physician if you experience any of the following symptoms: rapid or irregular
heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness,
irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting,
diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods,
hives or skin rash, or any other unusual medical event.
9. Notify your physician if you become pregnant while taking LEVOXYL ®. It is likely that
your dose of LEVOXYL® will need to be increased while you are pregnant.
10. Notify your physician or dentist that you are taking LEVOXYL® prior to any surgery.
11. Partial hair loss may occur rarely during the first few months of LEVOXYL® therapy, but
this is usually temporary.
12. LEVOXYL® should not be used as a primary or adjunctive therapy in a weight control
program.
13. Keep LEVOXYL® out of the reach of children. Store LEVOXYL® away from heat,
moisture, and light.
Laboratory Tests
General
The diagnosis of hypothyroidism is confirmed by measuring TSH levels using a sensitive assay (second generation assay sensitivity ≤0.1 mIU/L or third generation assay sensitivity ≤0.01
mIU/L) and measurement of free-T . 4
The adequacy of therapy is determined by periodic assessment of appropriate laboratory tests
and clinical evaluation. The choice of laboratory tests depends on various factors including the
etiology of the underlying thyroid disease, the presence of concomitant medical conditions,
including pregnancy, and the use of concomitant medications (see PRECAUTIONS , Drug
Interactions and Drug-Laboratory Test Interactions). Persistent clinical and laboratory evidence
of hypothyroidism despite an apparent adequate replacement dose of LEVOXYL ® may be
evidence of inadequate absorption, poor compliance, drug interactions, or decreased T4 potency of the drug product.
Adults
In adult patients with primary (thyroidal) hypothyroidism, serum TSH levels (using a sensitive
assay) alone may be used to monitor therapy. The frequency of TSH monitoring during
levothyroxine dose titration depends on the clinical situation but it is generally recommended at
6—8 week intervals until normalization. For patients who have recently initiated levothyroxine
therapy and whose serum TSH has normalized or in patients who have had their dosage or
brand of levothyroxine changed, the serum TSH concentration should be measured after 8—
12 weeks. When the optimum replacement dose has been attained, clinical (physical
examination) and biochemical monitoring may be performed every 6—12 months, depending
on the clinical situation, and whenever there is a change in the patient’s status. It is
recommended that a physical examination and a serum TSH measurement be performed at
least annually in patients receiving LEVOXYL ® (see WARNINGS , PRECAUTIONS , and
DOSAGE AND ADMINISTRATION ).
Pediatrics
In patients with congenital hypothyroidism, the adequacy of replacement therapy should be
assessed by measuring both serum TSH (using a sensitive assay) and total- or free- T .4 During the first three years of life, the serum total- or free- T4 should be maintained at all times in the upper half of the normal range. While the aim of therapy is to also normalize the serum
TSH level, this is not always possible in a small percentage of patients, particularly in the first
few months of therapy. TSH may not normalize due to a resetting of the pituitary-thyroid
feedback threshold as a result of in utero hypothyroidism. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of LEVOXYL® therapy
and/or of the serum TSH to decrease below 20 mU/L within 4 weeks should alert the physician
to the possibility that the child is not receiving adequate therapy. Careful inquiry should then be
made regarding compliance, dose of medication administered, and method of administration
prior to raising the dose
本文档为【Levoxyl (levothyroxine sodium) Tablet】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。